CNS Pharmaceuticals (CNSP) Corporate Media Kit

CNS pharmaceuticals 3 About Us. CNS IS DEVELOPING NOVEL ANTI-CANCER DRUG CANDIDATES FOR THE TREATMENT OF PRIMARY ANDMETASTATICBRAINCENTRALNERVOUS SYSTEMCANCERS. * A “complete response” to treatment means no signs of cancer are visible on MRI. This does not always mean the cancer is cured. Also called a complete remission: www.cancer.gov/publications/dictionaries/cancer-terms/def/complete-response • Founded in 2017 by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at University of Texas MD Anderson Cancer Center • IPO November 2019 – Nasdaq CNSP • Extremely efficient management: CEO John M. Climaco – 18 years in Pharma, Molecular Diagnostics & Med Device CFO Chris Downs – West Point, Columbia MBA, Investment Banking CMO Sandra Silberman MD PhD – Clinical Lead Gleevec CSO Don Picker PhD – Forty years of drug development experience • Lead Compound, Berubicin , is the first anthracycline that appears to cross the blood brain barrier Successful Phase 1 trial in GBM with 44% of patients experiencing a clinical benefit of stable disease or better, and one durable complete response • IND for potentially pivotal trial approved on December 16, 2020 • Strong pipeline for future development